产品封面图
文献支持

冬凌草甲素

收藏
  • ¥350
  • YOYOBIO
  • 上海
  • YJ-B20310-20mg
  • 2025年09月17日
    avatar
  • 企业认证

    点击 QQ 联系

  • 万千商家帮你免费找货

    0 人在求购买到急需产品
    • 详细信息
    • 文献和实验
    • 技术资料
    • 保存条件

      2-8℃

    • 保质期

      见包装

    • 英文名

      Oridonin

    • 库存

      大量现货

    • 供应商

      上海研谨生物

    • CAS号

      28957-04-2

    • 规格

      20mg

    冬凌草甲素

    分析标准品,HPLC≥98%

    Oridonin

    CAS号:28957-04-2

    分子式:C20H28O6

    分子量:364.43

    MDLMFCD00221762

    货号

    规格/参数/品牌

    价格

    货期

    YJ-B20310-20mg

    分析标准品,HPLC≥98%

    350.00

    现货

    JS28299-100mg

    98%

    600.00

    现货

    JS28299-1g

    98%

    2150.00

    现货

    JS28299-5g

    98%

    6200.00

    现货

    A10325-20mg

    分析标准品,含量94.8%,可溯源

    1600.00

    现货

     

    产品介绍

    Oridonin是从Rabdosia rubescens中得到的二萜,是一种AKT抑制剂,对 AKT1 AKT2 IC50值分别为 8.4 8.9 μM,具有抗菌、抗炎、抗肿瘤等功效。

    熔点:248-250℃

    沸点:599.8℃ at 760 mmHg

    比旋光度:(c, 0.1 in EtOH)-47

    外观:淡黄色针状结晶

    溶解性:DMSO  :  62.5  mg/mL  (171.50  mM;  Need  ultrasonic)

    储存条件:2-8℃

    注意:部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。

    风险提示:丁香通仅作为第三方平台,为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全,合理判断,谨慎选购商品,商家和用户对交易行为负责。对于医疗器械类产品,请先查证核实企业经营资质和医疗器械产品注册证情况。

    图标文献和实验
    该产品被引用文献

    参考文献(46)

    46. [IF=6.8] Kong Jiahui et al."Biomimetic MOFs Nanoparticles Co-Delivering Oridonin and siRNA for Synergistic Therapy in Melanoma via ferroptosis pathway."Journal of Science-Advanced Materials and Devices.2025 Jul;:100957

    45. [IF=5.4] Junli Zhang et al."Screening Isodon rubescens-Derived Vesicles Harvested at Different Periods as Carriers for the Treatment of Colitis-Associated Cancer."ACS Biomaterials Science & Engineering.2025;XXXX(XXX):XXX-XXX

    44. [IF=3] Jushuang Li et al."Oridonin ameliorates renal fibrosis in diabetic nephropathy by inhibiting the Wnt/β-catenin signaling pathway."RENAL FAILURE.

    43. [IF=6] Mengting Li et al."Design, synthesis, and biological evaluation of oridonin derivatives as novel NLRP3 inflammasome inhibitors for the treatment of acute lung injury."EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY.2024 Aug;:116760

    42. [IF=1.8] Gengzhen Huang et al."Oridonin attenuates diabetes‑induced renal fibrosis via the inhibition of TXNIP/NLRP3 and NF‑κB pathways by activating PPARγ in rats."EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES".2024 May;0:

    41. [IF=14.5] Mengru Cai et al."An iron-based metal-organic framework nanoplatform for enhanced ferroptosis and oridonin delivery as a comprehensive antitumor strategy."Acta Pharmaceutica Sinica B".2024 May;:

    40. [IF=4.6] Tianming Lu et al."Inhibition of ALDOA and ENO1-mediated Glycolysis of Oridonin as a Novel Anti-tumor Strategy of Non-small Cell Lung Cancer."Advanced Therapeutics".2024 Apr;:2400027

    39. [IF=5] Shiying Ye et al."Oridonin promotes RSL3-induced ferroptosis in breast cancer cells by regulating the oxidative stress signaling pathway JNK/Nrf2/HO-1."EUROPEAN JOURNAL OF PHARMACOLOGY".2024 Apr;:176620

    38. [IF=3.8] Zhang Feifan et al."Oridonin-induced ferroptosis and apoptosis: a dual approach to suppress the growth of osteosarcoma cells."BMC CANCER".2024 Dec;24(1):1-11

    37. [IF=4.5] Lunji Wang et al."Antibacterial Mechanisms and Antivirulence Activities of Oridonin against Pathogenic Aeromonas hydrophila AS 1.1801."Microorganisms".2024 Feb;12(2):415

    36. [IF=9.965] Mengru Cai et al."Enhanced lysosomal escape of cell penetrating peptide-functionalized metal-organic frameworks for co-delivery of survivin siRNA and oridonin."JOURNAL OF COLLOID AND INTERFACE SCIENCE.2023 Apr;:

    35. [IF=2.602] ZHOU Wei et al."Preparation and characterization of an oridonin and γ-cyclodextrin complex."Food Science and Technology.2022 Aug;42:

    34. [IF=5.811]

    33. [IF=2.248] Yang Huiyu et al."Selective synergistic anticancer effects of cisplatin and oridonin against human p53-mutant esophageal squamous carcinoma cells."Anti-Cancer Drug. 2022 Jan;33(1):e444-e452

    32. [IF=2.447] Yun Gui et al."Oridonin improves the therapeutic effect of lentinan on lung cancer."Exp Ther Med. 2021 Aug;22(2):1-9

    31. [IF=3] Qu  Lala et al."Phenotypic assessment and ligand screening of ETA/ETB receptors with label-free dynamic mass redistribution assay."N-S Arch Pharmacol. 2020 Jun;393(6):937-950

    30. [IF=3.361] Mengru Cai et al."Functionalization of MOF-5 with mono-substituents: effects on drug delivery behavior."Rsc Adv. 2020 Oct;10(60):36862-36872

    29. [IF=3.503] Lili  Tian et al."Preliminary safety assessment of oridonin in zebrafish."Pharm Biol. 2019;57(1):632-640

    28. [IF=3.591] Mengru Cai et al."Amino-functionalized Zn metal organic frameworks as antitumor drug curcumin carriers."New J Chem. 2020 Oct;44(41):17693-17704

    27. [IF=6.543] Hong Mu-keng et al."Oridonin Alters Hepatic Urea Cycle via Gut Microbiota and Protects against Acetaminophen-Induced Liver Injury."Oxid Med Cell Longev. 2021;2021:3259238

    26. [IF=0] Gan Zhao et al."Oridonin attenuates the release of pro-inflammatory cytokines in lipopolysaccharide-induced RAW264.7 cells and acute lung injury."Oncotarget. 2017 Sep 15; 8(40): 68153–68164

    25. [IF=1.785] Tao  Xu et al."Oridonin enhances in vitro anticancer effects of lentinan in SMMC‑7721 human hepatoma cells through apoptotic genes."Exp Ther Med. 2017 Nov;14(5):5129-5134

    24. [IF=2.833] Tian  Lili et al."Antiangiogenic effects of oridonin."Bmc Complem Altern M. 2017 Dec;17(1):1-15

    23. [IF=3.361] Jushuang Li et al."Oridonin protects against the inflammatory response in diabetic nephropathy by inhibiting the TLR4/p38-MAPK and TLR4/NF-κB signaling pathways."Int Immunopharmacol. 2018 Feb;55:9

    22. [IF=3.571] Xiangling  Xiao et al."Oridonin inhibits gefitinib-resistant lung cancer cells by suppressing EGFR/ERK/MMP-12 and CIP2A/Akt signaling pathways."Int J Oncol. 2016 Jun;48(6):2608-2618

    21. [IF=3.723] Yang Sun et al."Oridonin prevents epithelial-mesenchymal transition and TGF-β1-induced epithelial-mesenchymal transition by inhibiting TGF-β1/Smad2/3 in osteosarcoma."Chem-Biol Interact. 2018 Dec;296:57

    20. [IF=5.722] Liu  Qian-Qian et al."Oridonin inhibits pancreatic cancer cell migration and epithelial-mesenchymal transition by suppressing Wnt/β-catenin signaling pathway."Cancer Cell Int. 2016 Dec;16(1):1-8

    19. [IF=5.959] Lu  Ying et al."Oridonin exerts anticancer effect on osteosarcoma by activating PPAR-γ and inhibiting Nrf2 pathway."Cell Death Dis. 2018 Jan;9(1):1-16

    18.  Tian, L., Xie, K., Sheng, D. et al. Antiangiogenic effects of oridonin. BMC Complement Altern Med 17, 192 (2017). https:##doi.org/10.1186/s12906-017-1706-3

    17.  Zhao G, Zhang T, Ma X, et al. Oridonin attenuates the release of pro-inflammatory cytokines in lipopolysaccharide-induced RAW264.7 cells and acute lung injury. Oncotarget. 2017;8(40):68153-68164. Published 2017 Jul 12. doi:10.18632/oncotarget.19249

    16.  Xiao, X., He, Z., Cao, W., Cai, F., Zhang, L., Huang, Q., Fan, C., Duan, C., Wang, X., Wang, J., Liu, Y."Oridonin inhibits gefitinib-resistant lung cancer cells by suppressing EGFR/ERK/MMP-12 and CIP2A/Akt signaling pathways". International Journal of Onco

    15.  Yang Sun, Xiubo Jiang, Ying Lu, Jianwei Zhu, Lisha Yu, Bo Ma, Qi Zhang, Oridonin prevents epithelial-mesenchymal transition and TGF-β1-induced epithelial-mesenchymal transition by inhibiting TGF-β1/Smad2/3 in osteosarcoma, Chemico-Biological Interactions,

    14.  Jushuang Li, Liping Bao, Dongqing Zha, Lian Zhang, Ping Gao, Juan Zhang, Xiaoyan Wu, Oridonin protects against the inflammatory response in diabetic nephropathy by inhibiting the TLR4/p38-MAPK and TLR4/NF-κB signaling pathways, International Immunopharmaco

    13.  Cai, Mengru, et al. "Amino-functionalized Zn metal organic frameworks as antitumor drug curcumin carriers." New Journal of Chemistry 44.41 (2020): 17693-17704.DOI https:##doi.org/10.1039/D0NJ03680C

    12.  王倩,纠敏,孟媛媛,孔铭杰,殷成芮,汪伦记.冬凌草甲素/壳聚糖复合膜对冰鲜鸡胸肉的保鲜效果[J].食品与机械,2021,37(03):125-130.

    11.  李峥, 王强, 张晓莉. 蓝萼香茶菜提取溶剂的选择及其耐缺氧作用研究[J]. 中华中医药学刊, 2012, 030(006):1375-1377.

    10.  何中维 肖香玲 蔡芬 张亮 黄秋月 段超 刘莹.冬凌草甲素逆转人胃癌细胞SGC 7901/DDP顺铂耐药的作用及机制研究[J].湖北医药学院学报 2016 35(03):261-265+226.

    9.  尚曙玉  张铁山  郝海军 等. 冬凌草甲素磷脂复合物不同制剂在SD大鼠体内生物利用度的比较[J]. 中药材  2019  v.42;No.422(04):170-173.

    8.  杜利月  郭留城  郝海军 等. 冬凌草甲素渗透泵片制备工艺研究及体外评价[J]. 中药材  2018  v.41No.407(01):173-176.

    7.  田丽莉  盛东来  朱国福. 冬凌草甲素抑制血管生成活性及作用机制[J]. 中国实验方剂学杂志  2016  022(005):166-171.

    6.  纠敏  闫鹏  闫国庆 等. 冬凌草甲素对金黄色#葡萄*球菌的抑菌作用机制[J]. 江苏农业科学  2019  47(07):202-206.

    5.  纠敏  闫鹏  李晶晶 等. 冬凌草甲素对金黄色#葡萄*球菌生物膜的抑制机制[J]. 微生物学通报  2020  v.47(05):250-256.

    4.  田丽莉  朱国福  盛东来. 冬凌草甲素对人脐静脉内皮细胞的抑制作用[J]. 温州医学院学报  2017  047(012):880-883 887.

    3.  肖香玲 何中维 黄秋月 季娟丽 张云飞 刘莹.冬凌草甲素下调EGFR/ERK/MMP-12CIP2A/Akt信号通路抑制gefitinib耐受的非小细胞肺癌的转移[J].湖北医药学院学报 2016 35(06):536-542+629.

    2.  纠敏  孟媛媛  王倩 等. 冬凌草甲素/壳聚糖复合膜的性能和结构表征[J]. 食品与发酵工业  2019  045(024):119-123.

    1.  汪伦记  许美秋  纠敏 等. 冬凌草提取物对金黄色#葡萄*球菌生物膜形成的抑制作用[J]. 天然产物研究与开发  2017  029(006):1000-1005.

    相关实验
    • 层析柱的概念及其作用原理

      下的死体积应尽可能的小,如果支掌滤板下的死体积大,被分离组分之间重新混合的可能性就大,其结果是影响洗脱峰形,出现拖尾出象,降低分辩力。在精确分离时,死体积不能超过总床体积的1/1000。 以中压柱层析 法提取分离冬凌草甲素为例 中压分离层析柱 操作方法 以中压柱层析法提取分离冬凌草甲素为例 1 吸附剂的处理及柱子装填 将一定量薄层层析硅胶装人搪瓷盘置于烘箱中,于105。C活化2H后,取出放置室温即可装柱。柱子采用干法填充,填满整个柱体

    图标技术资料

    暂无技术资料 索取技术资料

    同类产品报价

    产品名称
    产品价格
    公司名称
    报价日期
    ¥200
    上海源叶生物科技有限公司
    2025年07月13日询价
    询价
    上海远慕生物科技有限公司
    2025年07月12日询价
    ¥300
    江西江蓝纯生物试剂有限公司
    2025年07月14日询价
    ¥1266
    上海玉博生物科技有限公司
    2025年07月08日询价
    ¥128
    合肥博美生物科技有限责任公司
    2025年07月02日询价
    文献支持
    冬凌草甲素
    ¥350